BiotechTube

etoricoxib + Other COX-2 inhibitor + nsNSAIDs

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
18
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Spondylarthropathies; Spondylitis, Ankylosing

Conditions

Spondylarthropathies; Spondylitis, Ankylosing

Trial Timeline

Feb 15, 2011 → Dec 6, 2018

NCT ID
NCT01327638

About etoricoxib + Other COX-2 inhibitor + nsNSAIDs

etoricoxib + Other COX-2 inhibitor + nsNSAIDs is a pre-clinical stage product being developed by Organon for Spondylarthropathies; Spondylitis, Ankylosing. The current trial status is completed. This product is registered under clinical trial identifier NCT01327638. Target conditions include Spondylarthropathies; Spondylitis, Ankylosing.

Hype Score Breakdown

Clinical
5
Activity
2
Company
5
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT01327638Pre-clinicalCompleted

Competing Products

3 competing products in Spondylarthropathies; Spondylitis, Ankylosing

See all competitors
ProductCompanyStageHype Score
SecukinumabNovartisPhase 3
77
EtanerceptPfizerApproved
84
MethotrexateOrion CorporationApproved
82

Other Products from Organon

desloratadineApproved
80
tibolone + raloxifenApproved
80
ezetimibe + statinsApproved
80
losartan potassium + Comparator: carvedilol + Comparator: losartan (+) hydrochlorothiazide (HCTZ) + Comparator: carvedilol (+) hydrochlorothiazideApproved
80
Desloratadine 5 mg + fexofenadineApproved
80